3895 results for «2025»
3895 results
LDL-C management: should it begin in the cathlab?
21 May 2026 – From EuroPCR 2026
This EuroPCR 2026 session examines the evolving role of LDL cholesterol management in patients undergoing percutaneous coronary intervention (PCI), with a focus on the potential benefits of initiating intensive lipid-lowering strategies early in the patient pathway.
The discussion reviews emerging evidence on PCSK9 inhibition in elective PCI...
Active unloading with Impella heart pumps in elective and emergent patients
21 May 2026 – From EuroPCR 2026
This session presents the latest evidence on the use of microaxial Impella heart pumps in both elective high-risk and emergent cardiogenic shock patients. It highlights the importance of organised systems of care in improving survival outcomes and explores current data and expert consensus on mechanical circulatory...
Ascending into the future with drug-coated balloons
21 May 2026 – From EuroPCR 2026
Step into the future of interventional cardiology with comprehensive insights into drug‑coated balloons (DCB). This session covers the new DCB ARC guidelines, previews findings from the impactful BASKET BALL randomised trial, and examines real-world evidence from the SCORE registry. It also addresses the optimisation of acute...
IVUS and NIRS imaging: a pathway to improve outcomes in stable and acute coronary syndromes
19 May 2026 – From EuroPCR 2026
IVUS-guided PCI is well established in complex coronary interventions, but combining it with near-infrared spectroscopy (NIRS) is opening a new dimension by linking vessel geometry with plaque biology.
This EuroPCR 2026session explores how IVUS-NIRS imaging improves PCI planning and risk stratification in both stable and acute coronary...
CathWorks FFRangio: from clinical data to advanced patient care
21 May 2026 – From EuroPCR 2026
Explore the clinical value of the CathWorks FFRangio system through the lens of the ALL-RISE randomised controlled trial and its implications for daily practice. By reviewing the trial’s primary and secondary endpoints, examine how FFRangio may influence diagnostic assessment, treatment planning, and clinical decision-making in patients...
The PCR-EAPCI Textbook is pleased to announce a new Editor-in-Chief!
22 May 2025
A formal handover took place on Wednesday, 21 May, in Paris during EuroPCR 2025, marking the transition from Stephan Windecker, former Editor-in-Chief, to Robert Byrne, who now assumes the role as the newly appointed Editor-in-Chief of this leading educational resource for interventional cardiologists.
NEO-MINDSET: Early withdrawal of aspirin after percutaneous coronary intervention for acute coronary syndrome
02 Sep 2025
Daniele Giacoppo reports and provides his perspective on the main results of the ambitious NEOMINDSET trial, presented by Pedro Lemos from the Hospital Israelita Albert Einstein, São Paulo, Brazil, during a Late Breaking Trials session at the ESC Congress 2025 in Madrid, and simultaneously published in the New...
Author
Season’s greetings and best wishes for a bright new year
17 Dec 2024
Listen to PCR Chairman William Wijns and Co-Chairmen Jean Fajadet and Bernard Prendergast wish the community a well-deserved relaxing and rejuvenating festive season. They look forward to enjoying your company, friendship and good humour at PCR Courses all around the globe in 2025.
What to expect at PCR Tokyo Valves?
Latest learnings on the treatment of asymptomatic severe aortic stenosis from the EARLY TAVR
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Christopher Cook, Philippe Genereux, and Victoria Delgado discuss key results from the EARLY TAVR study.
In asymptomatic patients with severe aortic stenosis, early intervention was associated with significantly less cardiac damage at 2 years, compared to a surveillance strategy that led to extensive damage...
First guidelines for the treatment of LM disease issued by SOLACI and SIAC
22 May 2025 – From EuroPCR 2025
During EuroPCR 2025, Cleverson Zukowski and Pablo Lamelas introduce a landmark initiative: the first clinical guidelines for left main disease specifically developed for Latin America.
Published by the Latin American Society of Interventional Cardiology (SOLACI) and the Interamerican Society of Cardiology (SIAC), these recommendations aim to support...
One year outcomes of transfemoral J-valve for chronic aortic regurgitation, a prospective multicenter study in 127 cases
20 May 2025 – From EuroPCR 2025
In this #europcr 2025 roundtable, Lai Wei and Dongming Hou present the latest data on the transfemoral J-Valve for chronic aortic regurgitation.
They begin with the China-DVD study, highlighting that aortic regurgitation is now slightly more prevalent than aortic stenosis in China. The conversation then shifts to...
Learnings from LANDMARK and Compare-TAVI at 3 years
22 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Andreas Baumbach, Christian Juhl Terkelsen and Didier Tchetche reviewed the latest findings from the LANDMARK and Compare-TAVI 1 trials—both focused on the performance of the Myval balloon-expandable valve.
LANDMARK compared Myval and Myval Octacor to leading self-expanding valves in a randomised controlled trial. At...
Learnings from Evolut Low Risk 5-year and SMART 2-year trials : from evidence to practice
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Angela McInerney, Didier Tchétché, and Ole De Backer discuss key results from the SMART and Evolut Low Risk trials. The SMART trial compared balloon-expandable and self-expanding valves in small annulus patients, showing better hemodynamics with the Evolut platform at 2 years. The Evolut...
Tricuspid TEER: learnings from the 2-year outcomes of TRILUMINATE Pivotal trial & bRIGHT study
20 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Marianna Adamo and Ralph Stephan von Bardeleben discussed the latest findings on tricuspid valve repair using transcatheter edge-to-edge repair (TEER).
The 2-year results from the TRILUMINATE Pivotal trial showed a significant reduction in tricuspid regurgitation, lasting improvements in quality of life, and a notable...
Focal or diffuse coronary disease: how can PPG measurement contribute to clinical decision-making?
22 May 2025 – From EuroPCR 2025
How can physiology guide treatment decisions beyond ischemia detection? In this round-table recorded at EuroPCR 2025, Thomas Engstrøm, Carlos Collet and Jeroen Sonck examine how pullback pressure gradient (PPG) makes it possible to identify the distribution pattern of coronary artery disease—focal or diffuse—based on a continuous...
Benefits of IVUS plus near-infrared spectroscopy in detecting and managing vulnerable plaques
21 May 2025 – From EuroPCR 2025
At EuroPCR 2025, Nilesh Pareek and Thomas Keeble discuss the clinical value and future potential of NIRS IVUS, a dual-modality imaging system developed by Nipro that combines intravascular ultrasound with near-infrared spectroscopy.
The Makoto™ system and Dualpro™ catheter allow real-time identification of lipid-rich plaques by providing both...
1-year SELUTION DeNovo results: drug-eluting balloon strategy vs. systematic drug-eluting stent in de novo coronary disease
29 Oct 2025
Guillaume Bonnet interviews Christian Spaulding about the SELUTION DeNovo Trial he presented at TCT 2025, in San Francisco.
Prof. Christian Spaulding, principal investigator of the study, discusses the trial design, key outcomes, breaks down the nuances behind the sirolimus DCB strategy versus contemporary DES, and shares insights...
Author
Author
Duration of DAPT in ACS: The DUAL-ACS Trial
31 Aug 2025
Ali Nazmi Calik interviews David Newby on the landmark DUAL-ACS trial results he presented at ESC Congress 2025 in Madrid.
The trial compared 3 months versus 12 months of dual antiplatelet therapy (DAPT) after myocardial infarction in an all-comer population. Findings suggest that shorter therapy may offer better...
Author
Author
Introducing our recognised EuroPCR Networkers!
